Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 

 Table of Contents  
Year : 2016  |  Volume : 12  |  Issue : 5  |  Page : 5-10

Laparoscopic jejunoileal side-to-side anastomosis for the treatment of type 2 diabetes mellitus in Chinese patients with a body mass index of 24–32 kg/m2

Department of Oncology Surgery, Xuzhou Central Hospital, Affiliated Hospital of Medical College of Southeast University, Xuzhou 221009, People's Republic of China

Date of Web Publication7-Oct-2016

Correspondence Address:
Minkang Zhang
Department of Oncology Surgery, Xuzhou Central Hospital, Affiliated Hospital of Medical College of Southeast University, Xuzhou 221009
People's Republic of China
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0973-1482.191618

Rights and Permissions
 > Abstract 

Objective: Laparoscopic jejunoileal side-to-side anastomosis (LJISSA) is an upcoming procedure that offers good metabolic improvement without causing significant malabsorption. The objective of this study was to evaluate the results of this novel procedure for the control of type 2 diabetes mellitus (T2DM) in patients with a body mass index (BMI) of 24–32 kg/m 2.
Materials and Methods: Fifty-seven patients with T2DM who underwent LJISSA between February 2010 and May 2013 were recruited in this study. Data collected included fasting blood glucose (FBG), 2 h postprandial blood glucose (2 h PBG), 1 h postprandial C peptide (1 h C-P), and glycosylated hemoglobin (HbA1c).
Results: Postoperatively, glycemic parameters (FBG and 2 h PBG, HbA1c and 1 h C-P) improved in all 57 patients. At 12 months, 34 patients had a remission of diabetes, and the remaining 23 patients showed a significantly decreased requirement for oral hypoglycemic agents. The patients with a BMI of 28–32 kg/m 2 had significant weight loss of between 7.8% and 20% (P < 0.05), whereas weight loss was not significant in those with a BMI of 24–28 kg/m 2. The group achieving remission had a higher BMI (28–32 kg/m 2), shorter duration of diabetes (<10 years), and higher stimulated C-P (>4 ng/mL). These three factors may be the predictors of diabetes resolution at 12 months.
Conclusion: LJISSA seems to be a promising procedure for the control of T2DM. A multicenter study with a larger number of patients and a longer follow-up period is needed to substantiate our preliminary findings.

Keywords: Gastric bypass, jejunoileal side-to-side anastomosis, metabolic surgery, type 2 diabetes mellitus

How to cite this article:
Li J, Xie G, Tian Q, Hu Y, Meng Q, Zhang M. Laparoscopic jejunoileal side-to-side anastomosis for the treatment of type 2 diabetes mellitus in Chinese patients with a body mass index of 24–32 kg/m2. J Can Res Ther 2016;12, Suppl S1:5-10

How to cite this URL:
Li J, Xie G, Tian Q, Hu Y, Meng Q, Zhang M. Laparoscopic jejunoileal side-to-side anastomosis for the treatment of type 2 diabetes mellitus in Chinese patients with a body mass index of 24–32 kg/m2. J Can Res Ther [serial online] 2016 [cited 2022 Aug 17];12, Suppl S1:5-10. Available from: https://www.cancerjournal.net/text.asp?2016/12/5/5/191618

 > Introduction Top

Type 2 diabetes mellitus (T2DM) is considered a pandemic or even a plague of the modern world. The global prevalence of diabetes among adults aged 20–79 years was estimated to be 6.4% in 2010, and it is projected to increase to 7.7% by 2030.[1] China has one of the largest diabetes mellitus populations in the world.[2] The total number of people in China with diabetes is projected to increase from 20.8 million in 2000 to 42.3 million in 2030.[3] This rise in diabetes prevalence has led to an intense search for some alternatives to the current treatment of T2DM and its consequences.

Currently, one of the most interesting alternatives is the surgical treatment of T2DM. It is well known that surgical procedures originally designed to treat morbid obesity may cause remission or significant improvement of T2DM. Traditionally, bariatric procedures have been reserved for patients with a body mass index (BMI) >40 kg/m 2, or >35 kg/m 2 for those with significant comorbidities. The remarkable impact of these operations on diabetes raises the possibility of surgical therapy for less obese patients with T2DM. Trials of Roux-en-Y gastric bypass (RYGB) in people with BMI <35 kg/m 2 have reported similar or even higher diabetes remission rates than those conducted in severely obese patients.[4],[5] Given that leaner individuals lose less total and percent body weight after RYGB than do more obese persons, the similarity in T2DM response hints that the operation might exert antidiabetic effects unrelated to weight loss.[6],[7],[8],[9] Consistent with this concept, experimental studies indicate that variations of RYGB improve T2DM in both obese and nonobese diabetic animals.[10],[11],[12],[13] Recent animal and clinical studies indicate that 50% to 60% of intestinal bypass or resection procedures can resolve diabetes in streptozotocin-induced diabetic rats [14] and restore glucose homeostasis in nonobese or mildly obese patients with T2DM.[15] Here, we present a new technique – called laparoscopic jejunoileal side-to-side anastomosis (LJISSA). The main goal was to offer all the known benefits of enhanced neuroendocrine response from faster stimulation of the distal bowel,[16],[17],[18],[19] without excluding or resecting any segments of the digestive tract. Jejunoileal side-to-side anastomosis is designed to allow partly undigested food into the distal ileum, and therefore would not significantly reduce intestinal absorption. This alteration of the intestinal tract aims to change the bowel's response to food intake and enhance incretin release, which ultimately has beneficial effects on pancreatic β-cell function and likely generates satiety signals.[16],[17],[18],[19] We, therefore, include selected nonobese and mildly obese patients with patients T2DM in our current study. We report the results of LJISSA treatment in 57 patients with T2DM, with a follow-up of 1 year.

 > Materials and Methods Top

The Scientific and Research Board of Southeast University and the Ethical Committee of Affiliated Xuzhou Hospital, Medical College of Southeast University of China, reviewed and approved the study protocol. All patients provided written informed consent after being informed thoroughly about the benefits and risks involved. Inclusion criteria for this study were as follows: age 18–65 years; BMI 24–32 kg/m 2, and poorly controlled T2DM as reflected by a glycosylated hemoglobin (HbA1c) level of ≥6.5%; a stimulated C-peptide (C-P) level of >1.5 ng/mL. Diagnosis of T2DM was based on the criteria of the American Diabetes Association and was considered valid if established by an endocrinologist or diabetes specialist.[20] The exclusion criteria were: type 1 diabetes mellitus; undetectable fasting C-P; positive urine ketones; pregnancy; coexisting severe hepatic, pulmonary, renal, cardiovascular, neurological, or psychiatric diseases; and obesity due to organic illness. LJISSA was performed in 57 patients between February 2010 and May 2013. All patients had been diagnosed with T2DM. Participants ranged in age from 29 to 60 years, had a duration of diabetes of 1 to 19 years, and preoperative BMI from 24 to 32 kg/m 2. Preoperatively, 39 (68.4%) patients required insulin or oral hypoglycemic agents (OHGAs), seven patients (12.3%) were receiving both insulin and OHGAs for glycemic control, and 11 (19.3%) other patients received no interventions for control. To evaluate the impact on LJISSA on patients with different mean BMI values, the patients were divided into two groups: Group A (24≤ BMI <28 kg/m 2, n = 27) and Group B (28≤ BMI <32 kg/m 2, n = 30). Before the operation, patients were assessed by a specialized team, including a surgeon, an endocrinologist, an anesthetist, a psychiatrist, and a dietician. Operative details recorded were operation time, duration of hospitalization, and complications, including early hemorrhage and bowel habit, until the last follow-up session. Follow-up visits were scheduled at 1 week and at 1, 3, 6, 9, and 12 months after surgery. Postoperative data collected included fasting blood glucose (FBG), 2 h postprandial blood glucose (2 h PBG), 1 h postprandial C-P (1 h C-P), HbA1c, medication usage, and BMI. If patients were not taking antidiabetic medications and had a normal FBG of <7.0 mmol/L and a normal HbA1c of <6.5%, their condition was considered resolved. Those with an HbA1c of ≤7% despite no use of antidiabetic medications were considered to have achieved glycemic control. If the FBG decreased by >1.4 mmol/L or the HbA1c decreased by >1%, the patients' condition was considered to have improved.

Operative procedure

The operation was performed under general anesthesia with a standard four-port laparoscopic technique. A 10-mm infra-umbilical optical port was inserted under direct visualization. A 30° laparoscope was used in all cases. Additional ports were placed as follows: a left subcostal port 5-mm port, a left infer-axillary 12-mm port, and a right infer-axillary 5-mm port. The surgical procedure involved marking the jejunum at 45 cm from the ligament of Treitz and the ileum at 60 cm proximal to the ileocecal junction. Both places were anastomosed side by side with an Endo GIA stapler (Echelon Endopath, Tyco, USA) with a 45-mm white cartridge, and the stapler openings were closed by the Endo GIA stapler with 60-mm cartridges in two layers. The mesenteric gaps were closed with hemlock (Tyco, USA) to prevent internal herniation. [Figure 1] shows a diagrammatic representation of the procedure.
Figure 1: Diagrammatic representation of the procedure

Click here to view

Postoperative follow-up

Postoperatively, diabetes medications were adjusted according to the plasma glucose levels. This operation is designed to shorten the transit time from jejunum to ileum and to change the bowel's response to food intake. Therefore, the patients started a liquid diet 1 day after surgery and continued it for 5–7 days, followed by a semisolid diet for another 7 days, and finally a solid diet, always in small quantities. They were asked to come for follow-up visits at 1, 3, 6, 9, and 12 months.

Statistical analysis

Microsoft Excel was used for data management. Statistical analyses were performed with SPSS 17.0 (http://www-01.ibm.com/software/analytics/spss/) statistical software. Data are expressed as mean (range) ± standard deviation. The Chi-square test or Fisher's exact test were used for categorical data. The unpaired t-test was used for parametric data. P < 0.05 was considered significant.

 > Results Top

A total of 57 patients underwent LJISSA (23 males and 34 females). Their baseline parameters are shown in [Table 1]. Postoperatively, 34 (59.6%) patients did not require insulin or OHGAs and maintained a normal FBG of <7.0 mmol/L and a normal HbA1c of <6.5%. More than 95.7% of the remaining 23 patients showed reductions in diabetes drug requirements. The mean operative time was 39 ± 13 min and the mean hospitalization time was 5 days (range 4–8 days). No intraoperative complications were noted, and none of the patients required conversion to open surgery. Postoperatively, there were no deaths, but 4 (7.0%) patients developed complications: One patient had an early hemorrhage at the jejunoileal anastomosis site, and the others had frequent loose stools. Postoperative follow-up data are shown in [Table 2]. In Group A, the change in mean BMI at 12 months compared to the mean preoperative BMI was significant (P < 0.01), while the mean BMI of Group B remained unchanged [Table 2]. LJISSA resulted in a marked improvement in the biochemical markers of diabetes [Table 3]. In the 57 patients, 1 h C-P levels were increased significantly from preoperative values at all postoperative assessments. Likewise, FBG and 2 h PBG decreased significantly from their preoperative values at all postoperative assessments. FBG and 2 h PBG were normalized in 15 (26.3%) and 9 (15.8%) patients, respectively, at 1 week, and in 39 (68.4%) and 30 (52.6%) patients, respectively, at 12 months. HbA1c was decreased significantly from preoperative values beginning at 1 month. About 34 (59.6%) patients achieved remission of T2DM, and the remaining 23 patients showed more than a 95.7% reduction in diabetes drug requirements and a 78.3% improvement in diabetes mellitus. We divided the patients into two groups according to three preoperative parameters: 28≤ BMI <32 kg/m 2 versus 24≤ BMI <28 kg/m 2, stimulated C-P (1 h postmeal) <4 ng/mL versus >4 ng/mL, and duration of diabetes ≤10 years versus >10 years. We found that the group that achieved remission after surgery seemed to have a greater BMI, greater stimulated C-P, and a shorter duration of diabetes [Table 4].
Table 1: Baseline data of the study group

Click here to view
Table 2: Postoperative comparison of body weight and body mass index in Groups A and B

Click here to view
Table 3: Postoperative metabolic parameters in 57 patients

Click here to view
Table 4: Diabetes remission data in different subgroups of patients

Click here to view

 > Discussion Top

All patients had considerable weight loss ranging from 5% to 18% of body weight. Diabetes control was good following surgery, with complete remission in 34 (59.6%) patients and more than a 95.7% reduction in diabetes drug requirements in the remaining 23 patients after 12 months. The remission persisted in all patients during the follow-up period. A trend was seen in lipid parameters, which decreased, although not to a statistically significant degree (data not shown). The definition of obesity according to BMI varies in different parts of the world. The WHO guidelines define obesity as >30 kg/m 2.[21] The cutoff value of BMI to define obesity in Asians is lower, and it is >28 kg/m 2 in China.[22] We selected a BMI cutoff value of ≥32.28 and 24 kg/m 2, respectively, for a diagnosis of morbid obesity, moderate obesity, and overweight in our study population, based on the available Asian data within different countries. In China, the BMI of the majority with T2DM ranges from 24 to 32 kg/m 2. Their islet function may be even worse according to the China Guideline for Type 2 diabetes. The purpose of jejunoileal side-to-side anastomosis is not to reduce gastrointestinal absorption but to reduce body weight to achieve the control of blood glucose, so we mainly selected moderate obesity and overweight patients for our study population with BMIs of 24–32 kg/m 2. Following surgery, there was significant reduction of weight from baseline in the range of 8.7%, 8.9%, and 9.6% at 3, 6, and 12 months, respectively, in the patients with a BMI of 28–32 kg/m 2. Correspondingly, a similar decline in BMI also was seen in this group, with reductions of 8.6%, 8.9%, and 9.6% at 3, 6, and 12 months, respectively. There was a slight reduction of weight and BMI in the patients with a BMI of 24–28 kg/m 2. A greater decline was seen in patients with higher BMIs. Overall, other studies evaluating the RYGB procedure have reported reductions in BMI in the range of 18% to 27%, and there were direct relationships between weight loss and preoperative BMI.[23],[24] Twelve months postsurgery, jejunoileal side-to-side anastomosis resulted in smaller reductions in BMI compared to RYGB. However, there was a remarkable glycemic improvement in all the 57 patients. The improvements in glycemic parameters (FBG, PBG, HbA1c, and 1 h post meal C-P) were statistically significant during follow-up at all the assessments. Postoperative glycemic improvement was disproportionately greater than weight loss, pointing to the independent benefits of the metabolic surgery. Based on this and available literature,[25],[26] patients with BMI <28 kg/m 2 were also subjected to this procedure and showed improvement in glycemic control with substantial reductions in antidiabetic agent requirements. There was a significant reduction of weight from the baseline of 9.6% at 12 months in the patients with BMI of 28–32 kg/m 2, but only a slight reduction of weight and BMI in the patients with BMI of 24–28 kg/m 2. In subgroups of BMI 24≤ BMI <28 kg/m 2 versus 28≤ BMI <32 kg/m 2, 55.6% versus 63.3% of patients had complete remission of diabetes, and the group that achieved higher remission 12 months after operation seemed also to have a higher weight loss. It is possible to explain the better improvement in the group with higher BMI because of the greater weight loss. In our center, some patients with T2DM with a BMI of 28≤ BMI <32 kg/m 2 and BMI ≥32 kg/m 2 chose duodenal-jejunal bypass and gastric bypass. At 1 year, there were significant reductions of weight from baseline of 13.5% and 18.9%, respectively, and 64.9% versus 82.3% of patients, respectively, had complete remission of diabetes, which is comparable to the results in the present study.

The changes in biochemical glycemic parameter in our patients confirm that LJISSA is effective in nonobese diabetic patients with BMI of 24–28 kg/m 2 to improve their glycemic and metabolic parameters. The key strengths of this study are the safety and efficacy of the surgery in treating patients with T2DM with a lower BMI, and the possibility of other achievements beyond glycemic control, which were suitable for our Chinese population. Possible mechanisms to explain the benefits of this procedure in nonobese patients could be as follows: earlier exposure of food to ileum, leading to a better incretin response [27] and ileal brake food partly entering into the ileum modulates gastric and intestinal motility to reduce food intake and absorption.[28] The surgical technique used in this study is designed essentially for diabetes control and utilizes hindgut mechanisms. LJISSA diverts partly undigested food into the ileum and possibly reduces ghrelin, a potent orexigenic substance that contributes significantly toward impaired glucose homeostasis.[29],[30],[31] Glucagon-like peptide 1 (GLP-1), the incretin responsible for the first phase of insulin secretion, is defective in T2DM. In jejunoileal side-to-side anastomosis, rapid stimulation of the ileal segment by ingested food possibly leads to augmented GLP-1 secretion.[32],[33],[34] Postprandial glucose homeostasis is determined not only by the stimulation of insulin secretion and suppression of hepatic glucose production, but also by the velocity of gastric emptying. GLP-1 also influences glucose metabolism by inhibiting glucagon secretion, decreasing hepatic gluconeogenesis, delaying gastric emptying, promoting satiety, suppressing appetite, and stimulating glycogenesis.

Higher remission rates of diabetes were observed in the group of patients with a higher BMI, shorter duration of diabetes (≤10 years), and higher stimulated C-P levels (>4 ng/mL). Measurement of stimulated C-P levels is a commonly accepted tool for assessing insulin secretion and function of the β-cell.[35],[36],[37] Previous studies have found an association between a higher success rate for bariatric surgery and a shorter duration of T2DM or a shorter duration of medication use and higher stimulated C-P.[38],[39] However, the accuracy of these factors as predictors of outcome in individual patients is limited. We hypothesize that the measurement of preoperative stimulated C-P levels and shorter duration of T2DM may have predictive power because it is a tool for assessing β-cell function. Multicenter studies on a larger number of patients with a longer follow-up period would strengthen our observations.

In nonobese subjects with T2DM, defective early insulin secretion after an oral glucose load is a key factor leading to hyperglycemia. This defective β-cell function is associated with a reduced early GLP-1 response. Metabolic surgery (LJISSA) corrects this defect,[25] and hence it is also beneficial in nonobese diabetic patients with BMI <28 kg/m 2. In this study, we investigated the confounding glucose-lowering effect induced at 7 days after surgery, independent of changes in the body weight. The underlying mechanisms responsible for the glucose-lowering effect induced by LJISSA remain to be completely explained. Previous studies have found that the redirection and enhancement of nutrient flow into the jejunum or ileum that is triggered shortly after a meal mediates the rapid glucose-lowering effect induced by proximal intestinal bypass operation, which is achieved through a reduction in endogenous glucose production.[40],[41],[42] Other studies have found that bile diversion seems to inhibit interdigestive and postprandial upper gut contractions in association with an increase of plasma peptide YY. Pancreatic juice was considered to play a role in the secretion of gastric inhibitory polypeptide.[43]

In the 57 patients who underwent LJISSA, there was a significant reduction of weight from baseline (9.6% at 1 year), in the patients with BMI of 28–32 kg/m 2, but a smaller reduction of weight and BMI in the patients with BMI of 24–28 kg/m 2. We found a very low rate of complications and no mortality in our study group. Thus, LJISSA appears to be a safe procedure. The average operating time (30–50 min) was much less than that required for RYGB and biliopancreatic diversion. Iron deficiency was not observed during the 1-year follow-up. Long-term data are needed to further establish the efficacy of this procedure.

 > Conclusion Top

This surgery based on the principle of neuroendocrine brake appears to be safe and a potentially effective option in the management of patients with T2DM. Patients with a higher BMI, shorter duration of diabetes, and higher stimulated C-P values should respond better. Further long-term data from a larger number of patients are necessary to define the role of this novel surgery in T2DM and related metabolic abnormalities.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.

 > References Top

Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:4-14.  Back to cited text no. 1
Pan C. Diabetes care in China: Meeting the challenge. World Hosp Health Serv 2005;41:29-30, 32.  Back to cited text no. 2
Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53.  Back to cited text no. 3
Cohen R, Pinheiro JS, Correa JL, Schiavon CA. Laparoscopic Roux-en-Y gastric bypass for BMI<35 kg/m (2): A tailored approach. Surg Obes Relat Dis 2006;2:401-4.  Back to cited text no. 4
Lee WJ, Wang W, Lee YC, Huang MT, Ser KH, Chen JC. Effect of laparoscopic mini-gastric bypass for type 2 diabetes mellitus: Comparison of BMI>35 and<35 kg/m 2. J Gastrointest Surg 2008;12:945-52.  Back to cited text no. 5
Lin E, Phillips LS, Ziegler TR, Schmotzer B, Wu K, Gu LH, et al. Increases in adiponectin predict improved liver, but not peripheral, insulin sensitivity in severely obese women during weight loss. Diabetes 2007;56:735-42.  Back to cited text no. 6
Gletsu N, Lin E, Khaitan L, Lynch SA, Ramshaw B, Raziano R, et al. Changes in C-reactive protein predict insulin sensitivity in severely obese individuals after weight loss surgery. J Gastrointest Surg 2005;9:1119-26.  Back to cited text no. 7
Foo J, Krebs J, Hayes MT, Bell D, Macartney-Coxson D, Croft T, et al. Studies in insulin resistance following very low calorie diet and/or gastric bypass surgery. Obes Surg 2011;21:1914-20.  Back to cited text no. 8
Umeda LM, Silva EA, Carneiro G, Arasaki CH, Geloneze B, Zanella MT. Early improvement in glycemic control after bariatric surgery and its relationships with insulin, GLP-1, and glucagon secretion in type 2 diabetic patients. Obes Surg 2011;21:896-901.  Back to cited text no. 9
Rubino F, Zizzari P, Tomasetto C, Bluet-Pajot MT, Forgione A, Vix M, et al. The role of the small bowel in the regulation of circulating ghrelin levels and food intake in the obese Zucker rat. Endocrinology 2005;146:1745-51.  Back to cited text no. 10
Rubino F, Marescaux J. Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: A new perspective for an old disease. Ann Surg 2004;239:1-11.  Back to cited text no. 11
Pacheco D, de Luis DA, Romero A, González Sagrado M, Conde R, Izaola O, et al. The effects of duodenal-jejunal exclusion on hormonal regulation of glucose metabolism in Goto-Kakizaki rats. Am J Surg 2007;194:221-4.  Back to cited text no. 12
Wang TT, Hu SY, Gao HD, Zhang GY, Liu CZ, Feng JB, et al. Ileal transposition controls diabetes as well as modified duodenal jejunal bypass with better lipid lowering in a nonobese rat model of type II diabetes by increasing GLP-1. Ann Surg 2008;247:968-75.  Back to cited text no. 13
Morsiani E, Carpanelli MC. Observations on the metabolic effects of partial jejunoileal bypass in streptozotocin-treated rats. Eur Surg Res 1985;17:25-32.  Back to cited text no. 14
Milleo FQ, Campos AC, Santoro S, Lacombe A, Santo MA, Vicari MR, et al. Metabolic effects of an entero-omentectomy in mildly obese type 2 diabetes mellitus patients after three years. Clinics (Sao Paulo) 2011;66:1227-33.  Back to cited text no. 15
Murphy KG, Dhillo WS, Bloom SR. Gut peptides in the regulation of food intake and energy homeostasis. Endocr Rev 2006;27:719-27.  Back to cited text no. 16
Gallagher TK, Geoghegan JG, Baird AW, Winter DC. Implications of altered gastrointestinal motility in obesity. Obes Surg 2007;17:1399-407.  Back to cited text no. 17
Rubino F, Zizzari P, Tomasetto C, Bluet-Pajot MT, Forgione A, Vix M, et al. The role of the small bowel in the regulation of circulating ghrelin levels and food intake in the obese Zucker rat. Endocrinology 2005;16:1745-51.  Back to cited text no. 18
Bose M, Oliván B, Teixeira J, Pi-Sunyer FX, Laferrère B. Do incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: What are the evidence? Obes Surg 2009;19:217-29.  Back to cited text no. 19
National Diabetes Information Clearinghouse. Diagnosis of diabetes. NIH Publication No. 09-4642. United States: US Department of Health and Human Services; 2008.  Back to cited text no. 20
Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults – The evidence report. National Institutes of Health. Obes Res 1998;6 Suppl 2:51S-209S.  Back to cited text no. 21
Bei-Fan Z; The Cooperative Meta-Analysis Group of Working Group on Obesity in China. Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults: Study on optimal cut-off points of body mass index and waist circumference in Chinese adults. Asia Pac J Clin Nutr 2002;11:S685-93.  Back to cited text no. 22
Nguyen NQ, Game P, Bessell J, Debreceni TL, Neo M, Burgstad CM, et al. Outcomes of Roux-en-Y gastric bypass and laparoscopic adjustable gastric banding. World J Gastroenterol 2013;19:6035-43.  Back to cited text no. 23
Villamizar N, Pryor AD. Safety, effectiveness, and cost effectiveness of metabolic surgery in the treatment of type 2 diabetes mellitus. J Obes 2011;2011:790683.  Back to cited text no. 24
Rask E, Olsson T, Söderberg S, Holst JJ, Tura A, Pacini G, et al. Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance. Metabolism 2004;53:624-31.  Back to cited text no. 25
Rubino F. Is type 2 diabetes an operable intestinal disease? A provocative yet reasonable hypothesis. Diabetes Care 2008;31 Suppl 2:S290-6.  Back to cited text no. 26
Hansen EN, Tamboli RA, Isbell JM, Saliba J, Dunn JP, Marks-Shulman PA, et al. Role of the foregut in the early improvement in glucose tolerance and insulin sensitivity following Roux-en-Y gastric bypass surgery. Am J Physiol Gastrointest Liver Physiol 2011;300:G795-802.  Back to cited text no. 27
Maljaars PW, Peters HP, Mela DJ, Masclee AA. Ileal brake: A sensible food target for appetite control. A review. Physiol Behav 2008;95:271-81.  Back to cited text no. 28
Broglio F, Arvat E, Benso A, Gottero C, Muccioli G, Papotti M, et al. Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab 2001;86:5083-6.  Back to cited text no. 29
Matzko ME, Argyropoulos G, Wood GC, Chu X, McCarter RJ, Still CD, et al. Association of ghrelin receptor promoter polymorphisms with weight loss following Roux-en-Y gastric bypass surgery. Obes Surg 2012;22:783-90.  Back to cited text no. 30
Chandarana K, Gelegen C, Karra E, Choudhury AI, Drew ME, Fauveau V, et al. Diet and gastrointestinal bypass-induced weight loss: The roles of ghrelin and peptide YY. Diabetes 2011;60:810-8.  Back to cited text no. 31
Jørgensen NB, Dirksen C, Bojsen-Møller KN, Jacobsen SH, Worm D, Hansen DL, et al. Exaggerated glucagon-like peptide 1 response is important for improved ß-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes. Diabetes 2013;62:3044-52.  Back to cited text no. 32
Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007;87:1409-39.  Back to cited text no. 33
Gault VA, Irwin N, Green BD, McCluskey JT, Greer B, Bailey CJ, et al. Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3) GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. Diabetes 2005;54:2436-46.  Back to cited text no. 34
Hills CE, Brunskill NJ. Cellular and physiological effects of C-peptide. Clin Sci (Lond) 2009;116:565-74.  Back to cited text no. 35
Luppi P, Cifarelli V, Wahren J. C-peptide and long-term complications of diabetes. Pediatr Diabetes 2011;12 (3 Pt 2):276-92.  Back to cited text no. 36
Brandenburg D. History and diagnostic significance of C-peptide. Exp Diabetes Res 2008;2008:576862.  Back to cited text no. 37
Vetter ML, Cardillo S, Rickels MR, Iqbal N. Narrative review: Effect of bariatric surgery on type 2 diabetes mellitus. Ann Intern Med 2009;150:94-103.  Back to cited text no. 38
Schauer PR, Burguera B, Ikramuddin S, Cottam D, Gourash W, Hamad G, et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg 2003;238:467-84.  Back to cited text no. 39
Troy S, Soty M, Ribeiro L, Laval L, Migrenne S, Fioramonti X, et al. Intestinal gluconeogenesis is a key factor for early metabolic changes after gastric bypass but not after gastric lap-band in mice. Cell Metab 2008;8:201-11.  Back to cited text no. 40
Chambers AP, Jessen L, Ryan KK, Sisley S, Wilson-Pérez HE, Stefater MA, et al. Weight-independent changes in blood glucose homeostasis after gastric bypass or vertical sleeve gastrectomy in rats. Gastroenterology 2011;141:950-8.  Back to cited text no. 41
Breen DM, Rasmussen BA, Kokorovic A, Wang R, Cheung GW, Lam TK. Jejunal nutrient sensing is required for duodenal-jejunal bypass surgery to rapidly lower glucose concentrations in uncontrolled diabetes. Nat Med 2012;18:950-5.  Back to cited text no. 42
Sato M, Shibata C, Kikuchi D, Ikezawa F, Imoto H, Sasaki I. Effects of biliary and pancreatic juice diversion into the ileum on gastrointestinal motility and gut hormone secretion in conscious dogs. Surgery 2010;148:1012-9.  Back to cited text no. 43


  [Figure 1]

  [Table 1], [Table 2], [Table 3], [Table 4]


Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

  >Abstract>Introduction>Materials and Me...>Results>Discussion>Conclusion>Article Figures>Article Tables
  In this article

 Article Access Statistics
    PDF Downloaded241    
    Comments [Add]    

Recommend this journal